Abstract 228P
Background
Cabozantinib, a novel TKI is an oral multitargeted inhibitor of VEGFR, MET and AXL kinases. The CABOSUN trial established the superiority of cabozantinib over sunitinib in newly diagnosed renal cell carcinoma (RCC) of intermediate or poor risk. Currently it is used as a single agent (intermediate risk) or in combination with nivolumab (intermediate and poor risk). However, data is lacking with respect to the real-world use patterns of cabozantinib.
Methods
In this study, we explored the use of single agent cabozantinib in advanced RCC in terms of dosing, effectiveness, tolerability, and toxicity profiles. This was a single center retrospective observational study from All India Institute of Medical Sciences, New Delhi, India. Data was collected retrospectively from prospectively maintained database. All eligible patients were aged 18 years or older, had measurable lesions, available case records, received at least 2 months of the drug and were evaluable for response.
Results
In total, 70 patients were identified with a median age of 53 years (interquartile, 47-65 years). Majority were males (81.4%). The different histologies were (clear cell 77.1%, papillary 11.4%, and translocation related 5.7%). 54.3% had prior nephrectomy. Majority had an IMDC score as intermediate (61.4%), followed by favorable (22.9%). Most common site of metastases was lung (60%) followed by bone (32.9%). Cabozantinib was started as the first line TKI in 60% (42/70), as 2nd line in 74.2% (23/31). Starting dose was 60mg in 27%, and 40mg in 73%. Dose reductions of cabozantinib were seen in 40.7% in 1st line, and 58.2% in 2nd line. Re escalation was done in 24.2%. Most common reason for dose reduction was diarrhea (64.7%). 35.7% had a partial response and 2.9% had a CR. ORR for overall population was 39.1%. Overall median PFS was 7.2 months. Most common adverse events were diarrhea in 42.7%, Hand-Foot skin reaction in 27.6%, mucositis in 17.8% and hepatotoxicity in 5.1%.
Conclusions
This study showed the practical dosing strategies and modifications of cabozantinib in the real world setting and how it differed from actual literature. We hope this study would help oncologists make better informed decisions while prescribing cabozantinib in advanced RCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
383P - Pre-treatment body mass index and neutrophil lymphocyte ratio predict 3-years progression free survival in locally advanced stage nasopharyngeal carcinoma
Presenter: Ni Putu Pusvita Dewi
Session: Poster Display
Resources:
Abstract
384P - Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan
Presenter: Wei-Chen Lu
Session: Poster Display
Resources:
Abstract
385P - The prognostic factors of induction chemotherapy followed by concurrent chemoradiotherapy in patients with HPV associated with oropharyngeal cancer
Presenter: Hyun Jin Bang
Session: Poster Display
Resources:
Abstract
386P - FOLR1 stabilized beta-catenin promotes laryngeal carcinoma progression through EGFR signal
Presenter: Huawei Tuo
Session: Poster Display
Resources:
Abstract
387P - A comprehensive analysis of the oral health status, tobacco use, and cancer prevalence among the tribal communities in India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
388P - Clinicopathological correlation of P53 expression in oral cancers
Presenter: Venkata Madhavi Bellala
Session: Poster Display
Resources:
Abstract
389P - Lack of cross-resistance to erlotinib in human head and neck cancer cells with acquired resistance to cetuximab
Presenter: James A. Bonner
Session: Poster Display
Resources:
Abstract
390P - Epidemiological aspects of the development of oral cancer in the Republic of Uzbekistan
Presenter: Akhrorbek Yusupbekov
Session: Poster Display
Resources:
Abstract
391P - Lip cancer: Racial disparities, treatment modalities and long-term survival outcome in young and adults versus older age patients
Presenter: FathAlrahman Ibrahim
Session: Poster Display
Resources:
Abstract
392TiP - A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy
Presenter: Juyi Wen
Session: Poster Display
Resources:
Abstract